A series of clinical trials designed to evaluate the cardiovascular safety of sodium-glucose transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) found that these medications have been shown to reduce major adverse cardiovascular events (MACE), including myocardial infarction (MI), hospitalization for heart failure (HF), and cardiovascular mortality [3]. This evidence concerns the gene GLP1R and myocardial infarction.